We continue strong commercial performance, prudent allocation of resources, and disciplined expense management.

Nov 9, 2023 / receipt, needs a key / Paul Edick, CEO | earnings call 2023-11-09 | transcript 6ccfe8af-b35e-4058-9ef5-c384804feace | chars 9820-9931 | segment 10

Through continued revenue growth, prudent allocation of resources, and disciplined expense management, we expect to hit the cash flow break-even point before year-end. This milestone should demonstrate to our shareholders that we can be a growing, self-sustaining biopharmaceutical company without the need for additional equity capital to fund our operations.

Aug 8, 2023 / receipt, needs a key / Paul Edith, CEO | earnings call 2023-08-08 | transcript 6be6cd59-6535-4430-bf41-03814aef575b | chars 14411-14771 | segment 14

Through continued revenue growth, careful allocation of resources, and prudent expense management, we expect to hit cash flow breakeven in the fourth quarter.

May 9, 2023 / receipt, needs a key / Paul, other | earnings call 2023-05-09 | transcript 04de1819-271c-45ba-b2e5-082b1696491f | chars 28750-28908 | segment 29

As we finish the year and head into 2023, we expect to build upon our 2022 momentum and continue creating shareholder value through continued revenue growth, careful allocation of resources, and proven expense management.

Nov 9, 2022 / receipt, needs a key / Paul Edic, CEO | earnings call 2022-11-09 | transcript 2925165f-ee0c-47db-a068-09d5f90f9820 | chars 14966-15187 | segment 15